| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
* Department of Medicine, St. George Clinical School and
Inflammation Research Unit, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia; and
Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick, MD 21702
Chemokines mediate trafficking of leukocytes to sites of inflammation and immune responses through activation of G protein-coupled receptors, which thereby provide appealing targets for novel anti-inflammatory agents. Vasoactive intestinal peptide (VIP) is an immunosuppressive neurotransmitter. We show that VIP inhibited the function of chemokine receptors on monocytes and CD4+ T lymphocytes, with impaired chemotaxis and calcium flux in response to the cognate chemokine ligands CXCL12, CCL3, CCL4, and CCL5. This was mediated by VIP receptor type 1 and was not caused by chemokine receptor internalization. However, VIP caused dose-dependent phosphorylation of the chemokine receptor CCR5. This trans-deactivation process was studied in a murine model of delayed-type hypersensitivity: continuous infusion of VIP resulted in significant abrogation of monocyte and lymphocyte infiltration. Circulating mononuclear cells from VIP-infused mice were unable to respond to chemokines. VIP may provide a novel approach to treatment of inflammatory diseases through inhibition of chemokine-dependent leukocyte recruitment.
This article has been cited by other articles:
|
|
 |
|
  R.P. GOMARIZ, Y. JUARRANZ, C. ABAD, A. ARRANZ, J. LECETA, and C. MARTINEZ VIP-PACAP System in Immunity: New Insights for Multitarget Therapy Ann. N.Y. Acad. Sci., July 1, 2006; 1070(1): 51 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gonzalez-Rey, A. Fernandez-Martin, A. Chorny, J. Martin, D. Pozo, D. Ganea, and M. Delgado Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis: Down-Regulation of Inflammatory and Autoimmune Responses Am. J. Pathol., April 1, 2006; 168(4): 1179 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. El-Shazly, P. Berger, P.-O. Girodet, O. Ousova, M. Fayon, J.-M. Vernejoux, R. Marthan, and J. M. Tunon-de-Lara Fraktalkine Produced by Airway Smooth Muscle Cells Contributes to Mast Cell Recruitment in Asthma J. Immunol., February 1, 2006; 176(3): 1860 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B M Lodde, F Mineshiba, J Wang, A P Cotrim, S Afione, P P Tak, and B J Baum Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome Ann Rheum Dis, February 1, 2006; 65(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhang and J. J. Oppenheim Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems J. Leukoc. Biol., December 1, 2005; 78(6): 1210 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zanin-Zhorov, G. Tal, S. Shivtiel, M. Cohen, T. Lapidot, G. Nussbaum, R. Margalit, I. R. Cohen, and O. Lider Heat Shock Protein 60 Activates Cytokine-Associated Negative Regulator Suppressor of Cytokine Signaling 3 in T Cells: Effects on Signaling, Chemotaxis, and Inflammation J. Immunol., July 1, 2005; 175(1): 276 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. POZO and M. DELGADO The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J, September 1, 2004; 18(12): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
